MOFFITT CANCER CENTER
The Sunshine Act requires manufacturers to report payments to teaching hospitals as institutions, separately from payments to individual physicians. These figures are money reported to the hospital itself — most of it research funding and grants, not compensation to any named doctor.
- Total reported
- $283.2M
- Transactions
- 19,183
- Companies
- 40
- Average per transaction
- $14,762
Who reported the payments
| Merck | $62,974,780 |
| Pfizer | $28,373,963 |
| Bristol Myers Squibb | $17,334,988 |
| E.r. Squibb & Sons, L.L.C. | $15,652,592 |
| Gilead | $13,907,758 |
| Novartis | $13,635,959 |
| Genentech, Inc. | $12,415,481 |
| Amgen | $12,241,174 |
| AstraZeneca | $10,354,440 |
| Regeneron | $10,242,393 |
| Exelixis Inc. | $7,673,997 |
| Janssen Research & Development, LLC | $6,745,737 |
| GSK | $5,645,142 |
| Incyte Corporation | $5,504,255 |
| Jazz Pharmaceuticals Inc. | $4,440,460 |
| AbbVie | $3,472,747 |
| Deciphera Pharmaceuticals Inc. | $3,394,524 |
| Seagen Inc. | $2,598,295 |
| Bayer | $2,373,575 |
| Astellas US Technologies | $2,331,470 |
| Daiichi Sankyo Inc. | $2,150,078 |
| Iovance Biotherapeutics, Inc. | $2,106,737 |
| Servier Bioinnovation | $1,854,904 |
| Clinigen, Inc. | $1,640,853 |
| Eisai Inc. | $1,516,365 |
| Acerta Pharma LLC | $1,389,137 |
| Eli Lilly | $1,376,209 |
| Alkermes, Inc. | $1,204,907 |
| Kyowa Kirin, Inc. | $1,203,838 |
| Lilly USA, LLC | $1,178,827 |
| Genmab U.S., Inc. | $1,170,350 |
| Takeda Pharmaceuticals U.S.A., Inc. | $1,131,273 |
| Astrazeneca UK Limited | $1,050,302 |
| Hoffmann-la Roche Limited | $1,020,163 |
| Epizyme, Inc. | $1,011,519 |
| Karyopharm Therapeutics Inc. | $971,303 |
| Trillium Therapeutics USA, LLC | $907,875 |
| Puma Biotechnology, Inc. | $860,667 |
| Cardinal Health 414 LLC | $830,000 |
| TG Therapeutics, Inc. | $812,619 |